	US 12,422,433 B2
	Blood biomarker that predicts persistent cognitive dysfunction after concussion
Robert Siman, Wilmington, DE (US)
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed by THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA (US)
Filed on Aug. 9, 2023, as Appl. No. 18/447,290.
Application 18/447,290 is a division of application No. 14/774,585, granted, now 11,761,959, previously published as PCT/US2014/027716, filed on Mar. 14, 2014.
Claims priority of provisional application 61/792,420, filed on Mar. 15, 2013.
Prior Publication US 2023/0393133 A1, Dec. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/566 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/566 (2013.01) [G01N 33/6896 (2013.01); G01N 2333/47 (2013.01); G01N 2333/4703 (2013.01); G01N 2800/28 (2013.01); G01N 2800/2871 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01)]

11 Claims

1. A method for providing a prognosis for and treating a subject having suffered from a computed tomography (CT)-negative mild traumatic brain injury (mTBI), said method comprising:

obtaining a serum or plasma sample from said subject;

analyzing said sample to determine the level of a serum or plasma concentration of calpain-cleaved αII-spectrin N-terminal fragment (SNTF);

comparing said level of said concentration of SNTF to the level of a pre-determined standard;

providing a prognosis for the subject having suffered from the mTBI based on the level of SNTF in the subject relative to the pre-determined standard, wherein an elevated level of SNTF relative to the pre-determined standard indicates an elevated risk of long-term neurological dysfunction; and

treating said mTBI in said subject.